Tamoxifen Citrate Tablet, Film Coated
NDC Package 72162-2209-3

11-digit billing NDC: 72162220903 · Billing unit: EA · 30 EA per package

Package Information

Tamoxifen Citrate tablets is metastatic Breast Cancer:Tamoxifen citrate tablets are effective in the treatment of metastatic breast cancer in women and men. This formulation utilizes a tablet, film coated delivery system. Marketed by Bryant Ranch Prepack, this product is identified by NDC 72162-2209 and is authorized under FDA application ANDA213358.

Identification & Billing

NDC Package Code
72162-2209-3
Package Description
30 TABLET, FILM COATED in 1 BOTTLE
Product Code
11-Digit Billing Format
72162220903
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
30 EA
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Tamoxifen Citrate
Non-Proprietary Name
Tamoxifen Citrate
Substance Name
Tamoxifen Citrate
Dosage Form
Tablet, Film Coated - A solid dosage form that contains medicinal substances with or without suitable diluents and is coated with a thin layer of a water-insoluble or water-soluble polymer.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
Usage Information
Metastatic Breast Cancer:Tamoxifen citrate tablets are effective in the treatment of metastatic breast cancer in women and men. In premenopausal women with metastatic breast cancer, tamoxifen citrate tablets are an alternative to oophorectomy or ovarian irradiation. Available evidence indicates that patients whose tumors are estrogen receptor positive are more likely to benefit from tamoxifen citrate tablets therapy.Adjuvant Treatment of Breast Cancer:Tamoxifen citrate tablets are indicated for the treatment of node-positive breast cancer in women following total mastectomy or segmental mastectomy, axillary dissection, and breast irradiation. In some tamoxifen citrate adjuvant studies, most of the benefit to date has been in the subgroup with four or more positive axillary nodes.Tamoxifen citrate tablets are indicated for the treatment of axillary node-negative breast cancer in women following total mastectomy or segmental mastectomy, axillary dissection, and breast irradiation.The estrogen and progesterone receptor values may help to predict whether adjuvant tamoxifen citrate tablets therapy are likely to be beneficial. Tamoxifen citrate tablets reduces the occurrence of contralateral breast cancer in patients receiving adjuvant tamoxifen citrate tablets therapy for breast cancer.Ductal Carcinoma in Situ (DCIS):In women with DCIS, following breast surgery and radiation, tamoxifen citrate tablets are indicated to reduce the risk of invasive breast cancer (see  BOXED WARNING  at the beginning of the label). The decision regarding therapy with tamoxifen citrate tablets for the reduction in breast cancer incidence should be based upon an individual assessment of the benefits and risks of tamoxifen citrate tablets therapy.Current data from clinical trials support five years of adjuvant tamoxifen citrate tablets therapy for patients with breast cancer.Reduction in Breast Cancer Incidence in High Risk Women:Tamoxifen citrate tablets are indicated to reduce the incidence of breast cancer in women at high risk for breast cancer. This effect was shown in a study of 5 years planned duration with a median follow-up of 4.2 years. Twenty-five percent of the participants received drug for 5 years. The longer-term effects are not known. In this study, there was no impact of tamoxifen on overall or breast cancer-related mortality (see  BOXED WARNING at the beginning of the label).Tamoxifen citrate tablets are indicated only for high-risk women. “High risk” is defined as women at least 35 years of age with a 5-year predicted risk of breast cancer ≥ 1.67%, as calculated by the Gail Model.Examples of combinations of factors predicting a 5-year risk ≥ 1.67% are:Age 35 or older and any of the following combination of factors:One first degree relative with a history of breast cancer, 2 or more benign biopsies, and a history of a breast biopsy showing atypical hyperplasia; orAt least 2 first degree relatives with a history of breast cancer, and a personal history of at least one breast biopsy; orLCISAge 40 or older and any of the following combination of factors:One first degree relative with a history of breast cancer, 2 or more benign biopsies, age at first live birth 25 or older, and age at menarche 11 or younger; orAt least 2 first degree relatives with a history of breast cancer, and age at first live birth 19 or younger; orOne first degree relative with a history of breast cancer, and a personal history of a breast biopsy showing atypical hyperplasia.Age 45 or older and any of the following combination of factors:At least 2 first degree relatives with a history of breast cancer and age at first live birth 24 or younger; orOne first degree relative with a history of breast cancer with a personal history of a benign breast biopsy, age at menarche 11 or less and age at first live birth 20 or more.Age 50 or older and any of the following combination of factors:At least 2 first degree relatives with a history of breast cancer; orHistory of one breast biopsy showing atypical hyperplasia, and age at first live birth 30 or older and age at menarche 11 or less; orHistory of at least two breast biopsies with a history of atypical hyperplasia, and age at first live birth 30 or more.Age 55 or older and any of the following combination of factors:One first degree relative with a history of breast cancer with a personal history of a benign breast biopsy, and age at menarche 11 or less; orHistory of at least 2 breast biopsies with a history of atypical hyperplasia, and age at first live birth 20 or older.Age 60 or older and:5-year predicted risk of breast cancer ≥ 1.67%, as calculated by the Gail Model.For women whose risk factors are not described in the above examples, the Gail Model is necessary to estimate absolute breast cancer risk. Health Care Professionals can obtain a Gail Model Risk Assessment Tool by dialing 1-866-850-2876.There are insufficient data available regarding the effect of tamoxifen citrate tablets on breast cancer incidence in women with inherited mutations (BRCA1, BRCA2) to be able to make specific recommendations on the effectiveness of tamoxifen citrate in these patients.After an assessment of the risk of developing breast cancer, the decision regarding therapy with tamoxifen citrate tablets for the reduction in breast cancer incidence should be based upon an individual assessment of the benefits and risks of tamoxifen citrate tablets therapy. In the NSABP P-1 trial, tamoxifen citrate tablets treatment lowered the risk of developing breast cancer during the follow-up period of the trial, but did not eliminate breast cancer risk (See Table 3 in  CLINICAL PHARMACOLOGY).

Regulatory & Marketing

Labeler Name
Bryant Ranch Prepack
Product Type
Human Prescription Drug
FDA Application #
ANDA213358
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
08-14-2020
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 72162-2209-3 identifies a specific commercial package of 30 tablet, film coated in 1 bottle of Tamoxifen Citrate, a human prescription drug labeled by Bryant Ranch Prepack. This product is billed for "EA" each discreet unit and contains an estimated amount of 30 billable units per package. This tablet, film coated is formulated for oral use and contains tamoxifen citrate as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Bryant Ranch Prepack on August 14, 2020. The current certification is valid through December 31, 2026.

How is this Bryant Ranch Prepack product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 72162220903. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 30 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
72162-2209-3
11-Digit CMS (5-4-2)
72162-2209-03

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.